The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications

International Reviews of Immunology

Volumn 35, Issue 4, 2016, Pages 325-339

  Hu, Jiemiao ^a   Yan, Jun ^a   Rao, Ganesh ^a   Latha, Khatri ^a   Overwijk, Willem W ^a   Heimberger, Amy B ^a   Li, Shulin ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

DC maturation; fibrin deposit; glioblastoma; immune suppression; inflammatory diseases; liver injury; membrane bound procoagulant; secreted immune checkpoint regulator; Tregs

Indexed keywords

FIBRINOGEN; FIBRINOGEN LIKE PROTEIN 2; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; FGL2 PROTEIN, HUMAN; FIBRIN; IMMUNOSUPPRESSIVE AGENT; T LYMPHOCYTE RECEPTOR;

ABORTION; BLOOD CLOTTING; CELL MATURATION; DENDRITIC CELL; GRAFT REJECTION; HUMAN; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LYMPHOCYTE PROLIFERATION; NEOPLASM; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; XENOGRAFT; ANIMAL; GLIOBLASTOMA; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM;

ANIMALS; BIOMARKERS; BLOOD COAGULATION; COSTIMULATORY AND INHIBITORY T-CELL RECEPTORS; FIBRIN; FIBRINOGEN; GLIOBLASTOMA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES, REGULATORY;

EID: 84939181477     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2014.956360     Document Type: Review

References (89)

1. T.Koyama, L.R.Hall, W.G.Haser, Structure of a cytotoxic T-lymphocyte-specific gene shows a strong homology to fibrinogen beta and gamma chains. Proc Nat Acad Sci USA 1987;84(6):1609–1613. PubMed PMID:3550794; PubMed Central PMCID:PMC304485.
2. C.Ruegg, R.Pytela. Sequence of a human transcript expressed in T-lymphocytes and encoding a fibrinogen-like protein. Gene 1995;160(2):257–262. PubMed PMID:7642106.
3. S.Yuwaraj, J.Ding, M.Liu, Genomic characterization, localization, and functional expression of FGL2, the human gene encoding fibroleukin:a novel human procoagulant. Genomics 2001;71(3):330–338. doi:10.1006/geno.2000.6444. PubMed PMID:11170750.
4. N.D.Rawlings, A.J.Barrett. Families of cysteine peptidases. Methods Enzymol 1994;244:461–486. PubMed PMID:7845226.
5. A.J.Barrett, N.D.Rawlings. Families and clans of serine peptidases. Arch Biochem Biophys 1995;318(2):247–250. doi:10.1006/abbi.1995.1227. PubMed PMID:7733651.
6. H.Liu, P.S.Yang, T.Zhu, Characterization of fibrinogen-like protein 2 (FGL2):monomeric FGL2 has enhanced immunosuppressive activity in comparison to oligomeric FGL2. Int J Biochem Cell Biol 2012;45(2):408–418. Epub 2012/11/07. doi:S1357-2725(12)00360-3 [pii] 10.1016/j.biocel.2012.10.014. PubMed PMID:23127799.
7. S.Marazzi, S.Blum, R.Hartmann, Characterization of human fibroleukin, a fibrinogen-like protein secreted by T lymphocytes. J Immunol 1998;161(1):138–147. PubMed PMID:9647217.
8. J.Mu, D.Qu, A.Bartczak, Fgl2 deficiency causes neonatal death and cardiac dysfunction during embryonic and postnatal development in mice. Physiol Genomics 2007;31(1):53–62. doi:10.1152/physiolgenomics.00026.2007. PubMed PMID:17550996.
9. I.Shalev, H.Liu, C.Koscik, Targeted deletion of fgl2 leads to impaired regulatory T cell activity and development of autoimmune glomerulonephritis. J Immunol 2008;180(1):249–260. PubMed PMID:18097026.
10. Q.Ning, D.Brown, J.Parodo, Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998;160(7):3487–3493. PubMed PMID:9531310.
11. C.Yang, Y.Chen, G.Guo, Expression of B and T lymphocyte attenuator (BTLA) in macrophages contributes to the fulminant hepatitis caused by murine hepatitis virus strain-3. Gut 2013;62(8):1204–1213. doi:10.1136/gutjnl-2012-302239. PubMed PMID:22637698.
12. P.A.Marsden, Q.Ning, L.S.Fung, The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis. J Clin Invest 2003;112(1):58–66. doi:10.1172/JCI18114. PubMed PMID:12840059; PubMed Central PMCID:PMC162293.
13. C.W.Chan, L.S.Kay, R.G.Khadaroo, Soluble fibrinogen-like protein 2/fibroleukin exhibits immunosuppressive properties:suppressing T cell proliferation and inhibiting maturation of bone marrow-derived dendritic cells. J Immunol 2003;170(8):4036–4044. PubMed PMID:12682232.
14. K.Su, F.Chen, W.M.Yan, Fibrinogen-like protein 2/fibroleukin prothrombinase contributes to tumor hypercoagulability via IL-2 and IFN-gamma. World J Gastroenterol 2008;14(39):5980–5989. PubMed PMID:18932275; PubMed Central PMCID:PMC2760190.
15. M.Liu, J.L.Leibowitz, D.A.Clark, Gene transcription of fgl2 in endothelial cells is controlled by Ets-1 and Oct-1 and requires the presence of both Sp1 and Sp3. Eur J Biochem/FEBS 2003;270(10):2274–2286. PubMed PMID:12752447.
16. G.A.Levy, M.Liu, J.Ding, Molecular and functional analysis of the human prothrombinase gene (HFGL2) and its role in viral hepatitis. Am J Pathol 2000;156(4):1217–1225. doi:10.1016/S0002-9440(10)64992-9. PubMed PMID:10751347; PubMed Central PMCID:PMC1876871.
17. J.W.Ding, Q.Ning, M.F.Liu, Fulminant hepatic failure in murine hepatitis virus strain 3 infection:tissue-specific expression of a novel fgl2 prothrombinase. J Virol 1997;71(12):9223–9230. PubMed PMID:9371581; PubMed Central PMCID:PMC230225.
18. H.Liu, P.S.Yang, T.Zhu, Characterization of fibrinogen-like protein 2 (FGL2):monomeric FGL2 has enhanced immunosuppressive activity in comparison to oligomeric FGL2. Int J Biochem Cell Biol 2013;45(2):408–418. doi:10.1016/j.biocel.2012.10.014. PubMed PMID:23127799.
19. I.D.McGilvray, Z.Lu, A.C.Wei, Murine hepatitis virus strain 3 induces the macrophage prothrombinase fgl-2 through p38 mitogen-activated protein kinase activation. J Biol Chem 1998;273(48):32222–32229. PubMed PMID:9822700.
20. Q.Ning, S.Lakatoo, M.Liu, Induction of prothrombinase fgl2 by the nucleocapsid protein of virulent mouse hepatitis virus is dependent on host hepatic nuclear factor-4 alpha. J Biol Chem 2003;278(18):15541–15549. doi:10.1074/jbc.M212806200. PubMed PMID:12594208.
21. Q.Ning, M.Liu, P.Kongkham, The nucleocapsid protein of murine hepatitis virus type 3 induces transcription of the novel fgl2 prothrombinase gene. J Biol Chem 1999;274(15):9930–9936. PubMed PMID:10187767.
22. M.Han, W.Yan, W.Guo, Hepatitis B virus-induced hFGL2 transcription is dependent on c-Ets-2 and MAPK signal pathway. J Biol Chem 2008;283(47):32715–32729. doi:10.1074/jbc.M806769200. PubMed PMID:18801734.
23. Y.Liu, L.Xu, Q.Zeng, Downregulation of FGL2/prothrombinase delays HCCLM6 xenograft tumour growth and decreases tumour angiogenesis. Liver Int:Official J Int Assoc Study Liver 2012;32(10):1585–1595. doi:10.1111/j.1478-3231.2012.02865.x. PubMed PMID:22925132.
24. M.Robertson. Fgl2:link between hepatitis B and SARS? Drug Discov Today 2003;8(17):768–770. PubMed PMID:12946632.
25. C.Drosten, S.Gunther, W.Preiser, Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348(20):1967–1976. doi:10.1056/NEJMoa030747. PubMed PMID:12690091.
26. T.Kohno, R.Moriuchi, S.Katamine, Identification of genes associated with the progression of adult T cell leukemia (ATL). Jpn J Cancer Res 2000;91(11):1103–1110. Epub 2000/11/28. PubMed PMID:11092974.
27. S.Auffermann-Gretzinger, E.B.Keeffe, S.Levy. Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood 2001;97(10):3171–3176. PubMed PMID:11342445.
28. T.T.Hecht, D.L.Longo, L.A.Matis. The relationship between immune interferon production and proliferation in antigen-specific, MHC-restricted T cell lines and clones. J Immunol 1983;131(3):1049–1055. PubMed PMID:6193170.
29. M.P.Everson, D.M.Spalding, W.J.Koopman. Enhancement of IL-2-induced T cell proliferation by a novel factor(s) present in murine spleen dendritic cell-T cell culture supernatants. J Immunol 1989;142(4):1183–1194. PubMed PMID:2644351.
30. E.Maraskovsky, W.F.Chen, K.Shortman. IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells. J Immunol 1989;143(4):1210–1214. PubMed PMID:2501391.
31. F.Wagner, N.Fischer, C.Lersch, Interleukin 4 inhibits the interleukin 2-induced production of its functional antagonist, interferon gamma. Immunol Lett 1989;21(3):237–241. PubMed PMID:2504666.
32. K.Taga, G.Tosato. IL-10 inhibits human T cell proliferation and IL-2 production. J Immunol 1992;148(4):1143–1148. PubMed PMID:1737931.
33. X.Han, K.Itoh, C.M.Balch, N.R.Pellis. Recombinant interleukin 4 (RIL4) inhibits interleukin 2-induced activation of peripheral blood lymphocytes. Lymphokine Res 1988;7(3):227–235. PubMed PMID:3263554.
34. J.D.Fontenot, J.P.Rasmussen, L.M.Williams, Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005;22(3):329–341. doi:10.1016/j.immuni.2005.01.016. PubMed PMID:15780990.
35. M.Miyara, S.Sakaguchi. Natural regulatory T cells:mechanisms of suppression. Trends Mol Med 2007;13(3):108–116. doi:10.1016/j.molmed.2007.01.003. PubMed PMID:17257897.
36. J.D.Fontenot, J.P.Rasmussen, M.A.Gavin, A.Y.Rudensky. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005;6(11):1142–1151. doi:10.1038/ni1263. PubMed PMID:16227984.
37. M.A.Gavin, J.P.Rasmussen, J.D.Fontenot, Foxp3-dependent programme of regulatory T-cell differentiation. Nature 2007;445(7129):771–775. doi:10.1038/nature05543. PubMed PMID:17220874.
38. L.Xie, N.Ichimaru, M.Morita, Identification of a novel biomarker gene set with sensitivity and specificity for distinguishing between allograft rejection and tolerance. Liver Transplantation:official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2012;18(4):444–454. doi:10.1002/lt.22480. PubMed PMID:22162188.
39. L.M.Williams, A.Y.Rudensky. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol 2007;8(3):277–284. doi:10.1038/ni1437. PubMed PMID:17220892.
40. Y.Zheng, S.Z.Josefowicz, A.Kas, Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 2007;445(7130):936–940. doi:10.1038/nature05563. PubMed PMID:17237761.
41. Y.Belkaid, B.T.Rouse. Natural regulatory T cells in infectious disease. Nat Immunol 2005;6(4):353–360. doi:10.1038/ni1181. PubMed PMID:15785761.
42. I.Shalev, K.M.Wong, K.Foerster, The novel CD4+CD25+ regulatory T cell effector molecule fibrinogen-like protein 2 contributes to the outcome of murine fulminant viral hepatitis. Hepatology 2009;49(2):387–397. doi:10.1002/hep.22684. PubMed PMID:19085958.
43. I.Shalev, N.Selzner, A.Helmy, The role of FGL2 in the pathogenesis and treatment of hepatitis C virus infection. Rambam Maimonides Med J 2010;1(1):e0004(1-12). doi:10.5041/RMMJ.10004. PubMed PMID:23908776; PubMed Central PMCID:PMC3721661.
44. Q.Li, A.J.Smith, T.W.Schacker, Microarray analysis of lymphatic tissue reveals stage-specific, gene expression signatures in HIV-1 infection. J Immunol 2009;183(3):1975–1982. doi:10.4049/jimmunol.0803222. PubMed PMID:19596987; PubMed Central PMCID:PMC3552354.
45. M.Han, W.Yan, Y.Huang, The nucleocapsid protein of SARS-CoV induces transcription of hfgl2 prothrombinase gene dependent on C/EBP alpha. J Biochem 2008;144(1):51–62. doi:10.1093/jb/mvn042. PubMed PMID:18390877.
46. H.Liu, I.Shalev, J.Manuel, The FGL2-FcgammaRIIB pathway:a novel mechanism leading to immunosuppression. Eur J Immunol 2008;38(11):3114–3126. doi:10.1002/eji.200838338. PubMed PMID:18991288.
47. T.Muta, T.Kurosaki, Z.Misulovin, A 13-amino-acid motif in the cytoplasmic domain of Fc gamma RIIB modulates B-cell receptor signalling. Nature 1994;368(6466):70–73. doi:10.1038/368070a0. PubMed PMID:8107887.
48. M.J.Nadler, B.Chen, J.S.Anderson, Protein-tyrosine phosphatase SHP-1 is dispensable for FcgammaRIIB-mediated inhibition of B cell antigen receptor activation. J Biol Chem 1997;272(32):20038–20043. PubMed PMID:9242674.
49. S.Tridandapani, M.Pradhan, J.R.LaDine, Protein interactions of Src homology 2 (SH2) domain-containing inositol phosphatase (SHIP):association with Shc displaces SHIP from FcgammaRIIb in B cells. J Immunol 1999;162(3):1408–1414. PubMed PMID:9973396.
50. A.Jacob, D.Cooney, S.Tridandapani, FcgammaRIIb modulation of surface immunoglobulin-induced Akt activation in murine B cells. J Biol Chem 1999;274(19):13704–13710. PubMed PMID:10224144.
51. J.V.Ravetch, S.Bolland. IgG Fc receptors. Ann Rev Immunol 2001;19:275–290. doi:10.1146/annurev.immunol.19.1.275. PubMed PMID:11244038.
52. G.K.Koski, L.A.Lyakh, P.A.Cohen, N.R.Rice. CD14+ monocytes as dendritic cell precursors:diverse maturation-inducing pathways lead to common activation of NF-kappab/RelB. Crit Rev Immunol 2001;21(1–3):179–189. PubMed PMID:11642603.
53. M.Neumann, H.Fries, C.Scheicher, Differential expression of Rel/NF-kappaB and octamer factors is a hallmark of the generation and maturation of dendritic cells. Blood 2000;95(1):277–285. PubMed PMID:10607713.
54. M.Liu, M.Mendicino, Q.Ning, Cytokine-induced hepatic apoptosis is dependent on FGL2/fibroleukin:the role of Sp1/Sp3 and STAT1/PU.1 composite cis elements. J Immunol 2006;176(11):7028–7038. PubMed PMID:16709865.
55. W.W.Hancock, F.M.Szaba, K.N.Berggren, Intact type 1 immunity and immune-associated coagulative responses in mice lacking IFN gamma-inducible fibrinogen-like protein 2. Proc Nat Acad Sci USA 2004;101(9):3005–3010. doi:10.1073/pnas.0308369101. PubMed PMID:14976252; PubMed Central PMCID:PMC365735.
56. G.A.Levy, P.J.MacPhee, L.S.Fung, The effect of mouse hepatitis virus infection on the microcirculation of the liver. Hepatology 1983;3(6):964–973. PubMed PMID:6313508.
57. P.J.MacPhee, V.J.Dindzans, L.S.Fung, G.A.Levy. Acute and chronic changes in the microcirculation of the liver in inbred strains of mice following infection with mouse hepatitis virus type 3. Hepatology 1985;5(4):649–660. PubMed PMID:2991107.
58. R.L.Parr, L.Fung, J.Reneker, Association of mouse fibrinogen-like protein with murine hepatitis virus-induced prothrombinase activity. J Virol 1995;69(8):5033–5038. PubMed PMID:7609073; PubMed Central PMCID:PMC189320.
59. R.J.Fingerote, M.Abecassis, M.J.Phillips, Loss of resistance to murine hepatitis virus strain 3 infection after treatment with corticosteroids is associated with induction of macrophage procoagulant activity. J Virol 1996;70(7):4275–4282. PubMed PMID:8676449; PubMed Central PMCID:PMC190359.
60. R.Khattar, O.Luft, N.Yavorska, Targeted deletion of FGL2 leads to increased early viral replication and enhanced adaptive immunity in a murine model of acute viral hepatitis caused by LCMV WE. PLoS One 2013;8(10):e72309(1-11). Epub 2013/10/23. doi:10.1371/journal.pone.0072309 PONE-D-13-01283 [pii]. PubMed PMID:24146739; PubMed Central PMCID:PMC3795679.
61. D.M.Pardoll. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12(4):252–264. doi:10.1038/nrc3239. PubMed PMID:22437870.
62. D.Cao, H.Xu, G.Guo, Intrahepatic expression of programmed death-1 and its ligands in patients with HBV-related acute-on-chronic liver failure. Inflammation 2013;36(1):110–120. doi:10.1007/s10753-012-9525-7. PubMed PMID:22895698.
63. D.Cao, H.Xu, G.Guo, Intrahepatic expression of programmed death-1 and its ligands in patients with HBV-related acute-on-chronic liver failure. Inflammation 2013;36(1):110–120. Epub 2012/08/17. doi:10.1007/s10753-012-9525-7. PubMed PMID:22895698.
64. Y.Chen, S.Wu, G.Guo, Programmed death (PD)-1-deficient mice are extremely sensitive to murine hepatitis virus strain-3 (MHV-3) infection. PLoS Pathogens 2011;7(7):e1001347(1-12). doi:10.1371/journal.ppat.1001347. PubMed PMID:21750671; PubMed Central PMCID:PMC3131267.
65. M.E.Keir, M.J.Butte, G.J.Freeman, A.H.Sharpe. PD-1 and its ligands in tolerance and immunity. Ann Rev. Immunol 2008;26:677–704. doi:10.1146/annurev.immunol.26.021607.090331. PubMed PMID:18173375.
66. K.Foerster, A.Helmy, Y.Zhu, The novel immunoregulatory molecule FGL2:a potential biomarker for severity of chronic hepatitis C virus infection. J Hepatol 2010;53(4):608–615. doi:10.1016/j.jhep.2010.04.020. PubMed PMID:20615566.
67. C.Li, L.S.Fung, S.Chung, Monoclonal antiprothrombinase (3D4.3) prevents mortality from murine hepatitis virus (MHV-3) infection. J Exp Med 1992;176(3):689–697. PubMed PMID:1324969; PubMed Central PMCID:PMC2119354.
68. M.Pope, O.Rotstein, E.Cole, Pattern of disease after murine hepatitis virus strain 3 infection correlates with macrophage activation and not viral replication. J Virol 1995;69(9):5252–5260. PubMed PMID:7636967; PubMed Central PMCID:PMC189358.
69. N.Selzner, H.Liu, M.U.Boehnert, FGL2/fibroleukin mediates hepatic reperfusion injury by induction of sinusoidal endothelial cell and hepatocyte apoptosis in mice. J Hepatol 2012;56(1):153–159. doi:10.1016/j.jhep.2011.05.033. PubMed PMID:21756857.
70. T.Chen, X.Ye, Z.Huang, Fgl2 prothrombinase is involved in severe acute pancreatitis-associated liver injury. Hepato-gastroenterology 2012;59(116):1225–1229. doi:10.5754/hge12117. PubMed PMID:22456282.
71. W.J.Chen, J.Y.Yang, J.H.Lin, Nasopharyngeal shedding of severe acute respiratory syndrome-associated coronavirus is associated with genetic polymorphisms. Clin Infectious Diseases (an official publication of the Infectious Diseases Society of America) 2006;42(11):1561–1569. doi:10.1086/503843. PubMed PMID:16652313.
72. De N.Albuquerque, E.Baig, X.Ma, Murine hepatitis virus strain 1 produces a clinically relevant model of severe acute respiratory syndrome in A/J mice. J Virol 2006;80(21):10382–10394. doi:10.1128/JVI.00747-06. PubMed PMID:17041219; PubMed Central PMCID:PMC1641767.
73. C.Zhu, Y.Sun, X.Luo, Novel mfgl2 antisense plasmid inhibits murine fgl2 expression and ameliorates murine hepatitis virus type 3-induced fulminant hepatitis in BALB/cJ mice. Human Gene Therapy 2006;17(6):589–600. doi:10.1089/hum.2006.17.589. PubMed PMID:16776568.
74. S.Gao, M.Wang, H.Ye, Dual interference with novel genes mfgl2 and mTNFR1 ameliorates murine hepatitis virus type 3-induced fulminant hepatitis in BALB/cJ mice. Human gene Therapy 2010;21(8):969–977. doi:10.1089/hum.2009.177. PubMed PMID:20218879.
75. F.H.Bach, H.Winkler, C.Ferran, Delayed xenograft rejection. Immunol Today 1996;17(8):379–384. PubMed PMID:8783499.
76. A.Ghanekar, M.Mendicino, H.Liu, Endothelial induction of fgl2 contributes to thrombosis during acute vascular xenograft rejection. J Immunol 2004;172(9):5693–5701. PubMed PMID:15100314.
77. M.Mendicino, M.Liu, A.Ghanekar, Targeted deletion of Fgl-2/fibroleukin in the donor modulates immunologic response and acute vascular rejection in cardiac xenografts. Circulation 2005;112(2):248–256. doi:10.1161/CIRCULATIONAHA.105.534271. PubMed PMID:15998670.
78. Q.Ning, Y.Sun, M.Han, Role of fibrinogen-like protein 2 prothrombinase/fibroleukin in experimental and human allograft rejection. J Immunol 2005;174(11):7403–7411. PubMed PMID:15905589.
79. D.A.Clark, G.Chaouat, P.C.Arck, Cytokine-dependent abortion in CBA × DBA/2 mice is mediated by the procoagulant fgl2 prothrombinase [correction of prothombinase]. J Immunol 1998;160(2):545–549. PubMed PMID:9551885.
80. M.Knackstedt, J.W.Ding, P.C.Arck, Activation of the novel prothrombinase, fg12, as a basis for the pregnancy complications spontaneous abortion and pre-eclampsia. Am J Reprod Immunol 2001;46(3):196–210. PubMed PMID:11554693.
81. D.A.Clark, K.Foerster, L.Fung, The fgl2 prothrombinase/fibroleukin gene is required for lipopolysaccharide-triggered abortions and for normal mouse reproduction. Mol Hum Reprod 2004;10(2):99–108. PubMed PMID:14742694.
82. K.Foerster, W.He, J.Manuel, LPS-induced occult loss in mice requires FGL2. Am J Reproduct Immunol 2007;58(6):524–529. doi:10.1111/j.1600-0897.2007.00543.x. PubMed PMID:17997751.
83. Y.Liu, S.Xu, F.Xiao, The FGL2/fibroleukin prothrombinase is involved in alveolar macrophage activation in COPD through the MAPK pathway. Biochem Biophys Res Commun 2010;396(2):555–561. doi:10.1016/j.bbrc.2010.04.145. PubMed PMID:20438701.
84. A.Young, O.Chapman, C.Connor, Thrombosis and cancer. Nat Rev Clin Oncol 2012;9(8):437–449. doi:10.1038/nrclinonc.2012.106. PubMed PMID:22777060.
85. Y.Kawakami, T.Yaguchi, H.Sumimoto, Cancer-induced immunosuppressive cascades and their reversal by molecular-targeted therapy. Ann NY Acad Sci 2013;1284:80–86. doi:10.1111/nyas.12094. PubMed PMID:23651199.
86. F.D.Birkhauser, R.C.Koya, C.Neufeld, Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma:efficacy, safety, and activity of Ad-GM.CAIX in immunocompetent mouse models. J Immunother 2013;36(2):102–111. Epub 2013/02/05. doi:10.1097/CJI.0b013e31827bec97. PubMed PMID:23377663.
87. Y.Liu, L.Xu, Q.Zeng, Downregulation of FGL2/prothrombinase delays HCCLM6 xenograft tumour growth and decreases tumour angiogenesis. Liver Int 2012. Epub 2012/08/29. doi:10.1111/j.1478-3231.2012.02865.x. PubMed PMID:22925132.
88. V.W.van Hinsbergh, A.Collen, P.Koolwijk. Role of fibrin matrix in angiogenesis. Ann NY Acad Sci 2001;936:426–437. Epub 2001/07/20. PubMed PMID:11460496.
89. M.E.Maragoudakis, N.E.Tsopanoglou, P.Andriopoulou. Mechanism of thrombin-induced angiogenesis. Biochem Soc Trans 2002;30(2):173–177. Epub 2002/05/25. doi:10.1042/. PubMed PMID:12023846.